Octreoscan(R) scintigraphy for gastro-entero-pancreatic neuroendocrine tumours
Medical Services Advisory Committee
Record ID 31999009749
English
Authors' objectives:
This report assesses OctreoScan(R) scintigraphy, which is a diagnostic test for the detection and localisation of gastro-entero-pancreatic neuroendocrine tumours.
Authors' recommendations:
MSAC recommended that on the strength of evidence relating to OctreoScan, public funding should be supported for this diagnostic test:
where there is a suspected GEP neuroendocrine tumour, based on biochemical evidence, with negative or equivocal structural imaging from conventional radiology (computed tomography or magnetic resonance imaging); or
where surgically amenable disease has been identified, based on biochemical evidence and conventional imaging, in order to rule out further metastatic disease.
Since there is currently insufficient evidence relating to the use of OctreoScan for the purposes of determining whether octreotide therapy is a viable therapeutic option, public funding should not supported at this time for this use.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.health.gov.au/haf/msac
Year Published:
1999
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Octreotide
- Endosonography
- Intestinal Neoplasms
- Pancreatic Neoplasms
- Stomach Neoplasms
Contact
Organisation Name:
Medical Services Advisory Committee
Contact Address:
MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name:
msac.secretariat@health.gov.au
Contact Email:
msac.secretariat@health.gov.au
Copyright:
Medical Services Advisory Committee
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.